Michel Vounatsos (Credit: World Economic Forum/Ciaran McCrickard)

Alzheimer's quick OK, take two: FDA of­fers Bio­gen, Ei­sai a short­cut to a pos­si­ble lecanemab ap­proval

Bio­gen CEO Michel Vounatsos is de­part­ing un­der a dark and wide cloud cre­at­ed by the Aduhelm fi­as­co, which es­sen­tial­ly de­stroyed any hope of any sub­stan­tial …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE